Company news

Mesoblast Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ODAC Votes in Favor of Remestemcel-L for GvHD

August 14, 2020

Update on Scheduled FDA Advisory Committee Meeting

August 11, 2020

COVID-19/GVHD Update, Quarterly Report and Appendix 4C

July 30, 2020

FDA Advisory Committee Sets Review Date for Remestemcel-L

July 20, 2020

S&P DJI Announces June 2020 Quarterly Rebalance

June 11, 2020

Remestemcel-L Improves Outcomes in Inflammatory Lung Disease

June 1, 2020

MSB Completes Financing For Covid-19 ARDS Manufacturing

May 13, 2020

Phase 2/3 Trial in COVID-19 ARDS Begins Enrollment

April 29, 2020

83% Survival in COVID-19 ARDS Patients with Remestemcel-L

April 24, 2020

US NIH Trials Network to Conduct COVID-19 Phase 2/3 Trial

April 8, 2020

FDA Clears IND for Remestemcel Use in COVID-19 ARDS Patients

April 5, 2020

FDA Accepts BLA for RYONCIL and Agrees to Priority Review

March 31, 2020

Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease

March 9, 2020

Mesoblast Provides Half Year Results and Corporate Update

February 26, 2020

Mesoblast Submits Completed BLA for Ryoncil to US FDA

February 2, 2020

Appendix 4C - quarterly

January 28, 2020

MSB Files GvHD Clinical Efficacy and Safety Data with US FDA

January 1, 2020

DMC Completes Final Review of Phase 3 Heart Failure Trial

December 17, 2019

CHF P3Trial Accrues Sufficient Primary EndPt Events(Correct)

December 16, 2019

CHF P3 Trial Accrues Sufficient Primary Endpoint Events

December 16, 2019

MSB Provides Q1 Financial Results and Operational Highlights

November 25, 2019

MSB and Lonza Enter GVHD Commercial Manufacturing Agreement

October 16, 2019

Mesoblast Raises A$75 Million

October 3, 2019

Grunenthal and MSB Enter Strategic Partnership for Back Pain

September 9, 2019

Mesoblast Reports on Annual Results

August 29, 2019

FDA Guidance on Clinical Pathway for LVAD Market Application

August 27, 2019

Appendix 4C - Quarterly, Strong Commercialization Revenues

July 31, 2019

Circulation Research Highlights MSB Heart Failure Therapy

July 24, 2019

FDA Grants Revascor Orphan Drug For End Stage CHF With LVADs

June 24, 2019

MSB Expands JCR Partnership To Brain Disease In Newborns

June 11, 2019

MSB Provides Q3 Financial Results and Operational Highlights

May 30, 2019

Mesoblast Initiates Rolling Submission of BLA for GvHD

May 29, 2019

MoU for Confirmatory Trial for GI Bleeding in LVAD Patients

March 26, 2019

MSB Licensee Files For Skin Disease Marketing Approval

March 24, 2019

MSB Draws US$15 Million From Existing Facility

January 13, 2019

P3 Trial of MSBs Cell Therapy in CHF Completes Recruitment

January 6, 2019

Response to ASX query

December 5, 2018

LVAD Results Webcast Presentation

November 12, 2018

LVAD Trial Results Provide Potential Regulatory Pathway

November 11, 2018

MSB Expands Partnership With JCR For Skin Disease

October 23, 2018

Completion of Tasly Transaction, and Appendix 3B

October 11, 2018

Day 180 Survival Outcomes In aGvHD Phase 3 Trial

September 20, 2018

Tasly Receives Approvals For Transaction With MSB

September 16, 2018

Mesoblast Reports on Annual and Fourth Quarter Results

August 29, 2018

Update on tasly transaction

August 28, 2018

MSB Enters Into Cardiovascular Alliance For China With Tasly

July 18, 2018

MSB Enters Into US$50M Financing With NovaQuest Capital

July 2, 2018

Key Day 100 Survival Results In P3 GvHD Trial

June 21, 2018

Partnership For Allogeneic Cell-based Cancer Immunotherapies

May 29, 2018

MSB Enters Into $75 Million Non-Dilutive Credit Facility

March 6, 2018

← Newer news releases · Older news releases →

Calls

The 5 newest of 10 calls. Every call is listed under its year.

Decks

The 5 newest of 105 decks. Every deck is listed under its year.